Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pacific Biomarkers Announces New Chief Scientific Officer

Published: Tuesday, January 03, 2012
Last Updated: Tuesday, January 03, 2012
Bookmark and Share
Pacific Biomarkers names the company's current Vice President, Research and Development, Amar A. Sethi, MD, PhD, as the new Chief Scientific Officer.

Dr. Sethi will succeed the current CSO and co-founder Elizabeth Teng Leary, PhD. Dr. Leary will assume a senior scientific advisory role while remaining active in scientific and business development activities at PBI.

Prior to joining the company, Dr. Sethi trained as a physician at the University of Copenhagen in Denmark (1996). In 2003 he was awarded a PhD in genetic epidemiology at the same institution, and in 2005 he became board certified in chemical pathology by the National Board of Health, Denmark. During 2005-2008 he was a postdoctoral fellow at the National Heart, Lung, and Blood Institute, Pulmonary and Vascular Medicine Branch, National Institutes of Health (NIH), and in 2008 he commenced a clinical chemistry fellowship in the Department of Laboratory Medicine, NIH, overseeing the Immunology Section while continuing his research. Dr. Sethi holds numerous awards and honors in both Denmark and the US, has presented extensively at international scientific meetings, and has published widely in international, peer-reviewed journals. His research has focused on genetic variations related to cardiovascular disease, and, most recently, on composition and function of HDL in patients with ischemic heart disease, and on apo-AI mimetic peptides in animal models of atherosclerosis. Currently, Dr. Sethi is focusing on innovative biomarkers to elucidate the role of HDL in cardiovascular disease.

Dr. Sethi was recently honored by R&D Directions as one of the "Most Notable People in R&D." R&D Directions' selection of the "Most Notable People in R&D" pays tribute to those who have led and made the significant breakthroughs in the discovery and development of drugs that indelibly change the ways in which particular diseases are treated.

"We are extremely pleased that a physician-scientist of Dr. Sethi's stature will be our CSO," commented Ron Helm, the company's CEO. "Amar is one of the leading scientists in the field and his work continues to reinforce our standing and reputation in the industry as the premier provider of esoteric testing services to pharma and diagnostic companies in the areas of cardiovascular, metabolic, and bone and joint diseases."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services.
Tuesday, March 11, 2014
Pacific Biomarkers' Dr. Amar A. Sethi Honored by Pharmaceutical Executive Magazine as One of 30 Emerging Pharma Leaders of 2011
Vice president of R&D called "A Pathfinder in Drug Development".
Wednesday, June 29, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!